Designing co-culture in existing microfluidic devices
• Creation of strong partnership
• Cell types & microfluidic devices
• Relevant and reproducible models
Together.
As part of our DNA, we focus on building the microfluidic architecture and model best suited to your research needs. We take your needs and translate them into the most relevant and reproducible microfluidic devices and/or models for you.
Co-development of new models
• Customized cell culture
• Customized readouts
• Existing microfluidic devices
Pre-clinical to clinical partnerships
• Fusion of cell types and microfluidic devices
• Relevant and reproducible models
Designing co-culture in existing microfluidic devices.
We know our chips are only worth how well hIPSCs and other cells grow and connect in them. We are always looking to adapt our devices to your cell culture needs, to offer you the most relevant and reproducible model for your research.
- With ETAP-Lab, we are currently developing three sets of neurological disorders models, using ETAP-Lab’s oligomers and NETRI’s microfluidic devices:
-
Alzheimer’s disease
-
Parkinson’s disease
-
Amyotrophic Lateral Sclerosis
- With Axol Bioscience, we are currently developing four sets of models, using Axol Bioscience’s hiPSC in NETRI’s microfluidic devices :
-
Peripheral nerve injury
-
Peripheral Neuropathic Pain
-
Allodynia & Nociceptive pain
-
Sensitive Skin.
- With Tessara Therapeutics, we combined our NeoBento™ neuro-organs-on-chip HT format with RealBrain® neural micro-tissues, to create a family of next generation drug discovery tools.
Co-development of new models.
NETRI has developped an internal process that mirrors NASA’s TRL levels as applied to Organ-on-Chip development. This provides a solid framework to help NETRI and its clients understand the level of maturity of a pre-clinical assay and focus the actions nescessary for completion. We offer co-development services tailored to your needs
- 1/ Idea: Generate the seed for an architecture and model that has potential for the drug development process.
- 2/ Concept: Translation to in vitro model.
- 3/ Architecture: Chip Prototyping & technological transfer to industrial standards.
- 4/ Cell culture: Ensuring repeatable and reliable cell culture protocols in the spectific architecture.
- 5/ Cell alteration: Providing tunable models relatively to a targeted disease.
- 6/ Readout: Establish high throughput readouts actionable with the model.
- 7/ Reference to golden standard shown: Establishing robustness of the model.
- 8/ Regulatory approved: Provide predictable and regulatory approved models.
Pre-clinical to clinical partnerships.
NETRI’s organs-on-chip devices are designed to accommodate cells from a diverse array of species, encompassing human, rodents, non-human primates, dogs, mini pigs, and more, whether they be primary or derived from iPSC. This exceptional compatibility across species empowers researchers to conduct cross-species investigations, therefore gaining translational confidence while executing in vitro tests that offer predictive insights into clinical outcomes. Moreover, NETRI provides culture protocols adapted to the specific species employed and tools to facilitate widespread adoption of this model among all relevant stakeholders.
To bridge the gap in genetic variability between conventional in vitro models/in vivo animal models and the reality of the heterogeneity and specificity of the human genome, NETRI, through collaboration with biobanks and suppliers of biological material and cells, is seeking to develop a French cohort-on-chip offer, making it possible to target specific genetic predispositions or, on the contrary, to ensure genetic variability representative of the human species.
